Related coverage linked through entity extraction aliases.
Mar 18, 2026
Candel Therapeutics secured $100M royalty funding for CAN-2409 and plans a Q4 2026 BLA submission in prostate cancer. Updated NSCLC phase 2a data showed median overall survival of 25.4 months, with a phase 3 trial planned for Q2 2026.
Jul 29, 2026
Candel initiated the Phase 3 AURORA trial of aglatimagene in NSCLC and plans a Q4 2026 BLA in localized prostate cancer, with a potential 2027 launch. The company also appointed a Chief Commercial Officer.
Jul 22, 2026
A large clinical trial found that adding apalutamide to hormone therapy before and after prostate cancer surgery improves outcomes for high-risk patients. NHS England will roll out SABR radiotherapy requiring only five sessions, and new ctDNA and robotic biopsy technologies are advancing prostate cancer care.
Feb 27, 2026
A multi-institutional study found that pairing an investigational immunotherapy with hormone therapy before surgery reduced regulatory T cells in prostate tumors and improved cancer-free outcomes in high-risk patients.
Feb 20, 2026
Candel Therapeutics announced a $100 million royalty funding agreement with RTW Investments, contingent on FDA approval of aglatimagene besadenovec for intermediate- to high-risk localized prostate cancer, with tiered royalties on U.S. net sales.
Feb 13, 2026
A matched analysis of 923 men found salvage focal therapy and radical prostatectomy achieved comparable 10-year cancer-specific survival for prostate cancer recurring after radiotherapy, though surgery carried significantly higher complication rates.
